Clinical Trial Update: Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial in Saudi Arabia is evaluating caffeine as an adjuvant therapy for late preterm infants with respiratory distress, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Respiratory Distress Syndrome
• Preterm Birth

Drugs mentioned

• Caffeine (caffeine)

Snippet

Sponsor: Ministry of Health, Saudi Arabia | Conditions: Prematurity, Respiratory Disease | Phase 2, Phase 3 | Status: RECRUITING